Marte Fauskanger
Oslo, Norway
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Chimeric antigen receptor T cells targeting the GM3(Neu5Gc) ganglioside.
Journal: Frontiers in immunology
Published: October 31, 2023
CD4+ T-cell killing of multiple myeloma cells is mediated by resident bone marrow macrophages.
Journal: Blood advances
Published: January 02, 2020
CD4+ T cells indirectly kill tumor cells via induction of cytotoxic macrophages in mouse models.
Journal: Cancer immunology, immunotherapy : CII
Published: February 25, 2019
Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models.
Journal: Communications biology
Published: December 01, 2018
Tumor Killing by CD4+ T Cells Is Mediated via Induction of Inducible Nitric Oxide Synthase-Dependent Macrophage Cytotoxicity.
Journal: Frontiers in immunology
Published: April 24, 2018
CD4+ T-cell-Mediated Rejection of MHC Class II-Positive Tumor Cells Is Dependent on Antigen Secretion and Indirect Presentation on Host APCs.
Journal: Cancer research
Published: October 16, 2017
Tumor-specific CD4+ T cells eradicate myeloma cells genetically deficient in MHC class II display.
Journal: Oncotarget
Published: May 06, 2016
Idiotype-specific CD4(+) T cells eradicate disseminated myeloma.
Journal: Leukemia
Published: October 10, 2015
Tumors Escape CD4+ T-cell-Mediated Immunosurveillance by Impairing the Ability of Infiltrating Macrophages to Indirectly Present Tumor Antigens.
Journal: Cancer research
Published: December 11, 2014
How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?
Journal: Frontiers in immunology
Published: February 17, 2014
Showing 1-12 of 12
Last Updated: 09/26/2026